Member Info for Tiger16

New unlce , I can assure you this is not going to go private , for one simple reason , they have intentionally mislead investors in RNS , and money is clearly missing , they need to get this trading to ensure there is no issues raised by the FCA .. That is what I have been told by investment bankers ..

I believe that that the new CEO will have this back trading or the cornerstone share holder will buy us out ..

Guys The message was in the interview and could not of been much clearer .. WE need a healthy cash balance to neg a deal with the big boys .. News is on the way .. and this will rocket .. to a another level ...

Guys nearly half a millions in share value has been sold off , hence of course the share price will reflect this for a few days , unless significant news land in real time shortly .. which I believe is now days away ..

St martins , interesting information and research , which is exactly what one needs to do when in Investing , more importantly one needs or would be in a prime position should they have insight due to information from Institutional investors and those working in the same environment ( space ) in real time .

Hence I reiterate , Our CEO is looking to retire , and has no intention of becoming a mining company .. The facts are clear , the JOK report is due anytime now , and the Listing for Metlen is good to go , and will be even more attractive with Rocks asset ..

Many will be locked out when news lands and this will open at a re rate ..

The above is not financial advice .. its common sense ..

My banker fried (sells insurance at Halifax, just gave me this anal ysis) Skeptical Analysis:

25-Year Journey: While longevity can indicate resilience, a 25-year timeline without a major commercial breakthrough might raise concerns about execution or strategic focus. Many successful biotech firms have achieved market traction or partnerships within a decade.

P140 Platform: While the P140 platform sounds promising, the interview lacks concrete, peer-reviewed data or clinical milestones that validate its efficacy. Competitors like Aurinia Pharmaceuticals (Lupkynis for lupus nephritis) have demonstrated clear clinical results.

Lanstead Agreement: The fundraising agreement with Lanstead Capital involves a sharing agreement, which can sometimes lead to share price volatility. Lanstead's history with other companies should be reviewed to assess the potential impact on shareholder value.

Oversubscribed Fundraising: An oversubscribed round is a positive sign, but more details on investor profiles and the strategic value they bring would be helpful. Are these long-term biotech investors or more speculative players?

Lupuzor Past Challenges: The interview does not address past challenges with Lupuzor's clinical trials, particularly the missed endpoints. A clear plan to overcome these hurdles would build more confidence.

P140 Platform Potential: If the P140 platform can address autoimmune diseases effectively, this could be a blockbuster opportunity. The autoimmune market is large and growing, with significant unmet needs.

Strategic Partnership with Lanstead: While not without risk, the Lanstead agreement provides a sustained capital flow, which can support long-term development without immediate equity dilution.

Investor Interest: An oversubscribed round indicates strong market interest, suggesting that the biotech investment community sees potential in ImmuPharma’s pipeline.

CEO’s Experience: Tim’s 25-year commitment to ImmuPharma demonstrates resilience and a deep understanding of the business and market landscape. His experience could be a stabilizing factor in volatile biotech markets.

Broader Market Context: With advancements in autoimmune treatments and a growing focus on chronic diseases, ImmuPharma is well-positioned if it can bring its therapies to market.

Strategic Suggestions for Tim:

Improve Transparency: Provide regular, detailed updates on clinical progress, including both positive developments and challenges.

Clinical Milestones: Share specific, measurable milestones for the P140 platform to build investor confidence.

Leverage Partnerships: Consider strategic partnerships or collaborations with larger pharmaceutical companies to enhance credibility and accelerate development.

Expand Investor Base: Target institutional investors with a long-term focus, reducing exposure to share price volatility.

Commercial Strategy: Develop a clear commercialization plan for Lupuzor and other pipeline can

"IloveSUSHI " no my fishy friend , you've caught the wrong end of the rod on this one.

lanstead doesn’t work like the usual death spiral financiers u see dragging stocks down. they only win if imm wins. think about it – their model is based on a profit-sharing arrangement, meaning they benefit when the share price goes up, not down. if they were just looking to dump, why would they agree to a deal where they get more money if the price rises? makes zero sense.

the reality is, lanstead backs companies they see as future multi-baggers. look at history – they’ve been involved in plenty of firms that went on massive runs once their tech matured. they don’t do charity. they smell big money.

imm isn’t getting “shafted” here – they just secured nearly £2m in strategic funding at a time when markets are brutal for biotech. that’s a major vote of confidence, not a red flag. and remember, placing was oversubscribed – demand is already outstripping supply. what happens when that demand keeps building? 🚀

let them try and shake weak holders out, let the shorts play their silly games – real investors see what’s coming. big pharma watching, royal garden party whispers, nobel prize potential – this is the start of a major rerate. stay strong, don’t get played by the FUD! 💎🔥

Our CEO , is actually very limited to what he would really like to say , as it would be price sensitive .. against regulations to even mention who they are speaking too .. Yet he dropped a hint , that we need to have a strong cash balance when Neg , or its the big boys with the little boys deal .. low ball offers .. hence this is now not the case , and when that offer is confirmed , He is not going to hang around .. sell , retire .. end of .. the longer this goes on the more the buy out price becomes as does the share price , and our return ..

Guys If you follow my posts , I relayed that IMM need to have a strong cash balance when Neg with billions dolor Pharma s .. its that simple , he has dropped enough hints , and talks are advanced here with BIG Pharma s ..

This is one of those stocks you just cant be out of even for a minute ..

When there is a late stage asset , the Big fishes will know now , IMM have cash , and can get more .. hence the further They develop ground Breaking drug, the more expensive it becomes and all the big fishes want in ..

Now is the time ...

The above is not financial advice .. its common sense

CTSFO , totally agree , Trump will not rest until he secures these minerals , as he will not give in to china , This Ukrane and Russia situation is the not going to work out .. He needs to find a new or a second option for these minerals , but guess what , There are big mining companies who will be circling around Greece hence Melton will not loose this opportunity to take over Rock before someone else gets in ..

I believe we should be hearing from our New CEO shortly , this radio silence is basically not very professional and from Roberts history , he is a very professional business leader .. Hence their must be some news that he is either awaiting or proactive in now , one would imagine that a New CEO would have a preference to deliver his first RNS singing to the tune of success and progress moving forward ..

We can be far from news on the developments of one of the big Pharma taking over IMM .. just my opinion .. watch this space ...

The next news here will be the very likely the Take over of Rock by Melton ... Melton are now very close to listing on the LSE .. they need Rock on their books ...

A sell well that isnt good news then ?

Guys was the 35 k a buy or sell ?

Guys I share your enthusiasm , yet I will go by my research , if you know what I mean.. Metlen will not be paying pounds for this early intervention of a buy out , hence I believe due to advice from experience and familiar with the matter , that the buy out will be between 5 - 6 p a share ..

Guys have confidence in todays RNS , Our new CEO has not resigned and the AGM went ahead even though we all mis read the last RNS , which confirms no one has lied ..

Hence we should have the audit completed way before end of April , time was bought very cleverly , and was bought for a reason .

Also it seems they are not happy with the current Audit company .. which could be the delay ..

I expressed over the weekend , That R have sold out for one reason only , bad investment decisions in two other companies , this is what I have been advised by My investment bankers .. they are is serious trouble ..

Now we are at the cusp of a break through deal with Melton , hence the SP will now re rate , Friday was a big day and one that was a gift , I wish i had more funds to buy in then , yet I have already gone in big here .. so no regrets ..

Guys wake up .. I cant predict the share price in the coming days after friday .. I do know that when Melton announce they have bought Rock .. no one will see the share price going crazy and be locked out as it will be NT all day long as this flies to 2p plus .. remember my words ..

The news , the reports , China ban heating up and Europe need Greece to come through like Greece need GDP

For those who are confused here , allow me to be more expressive .. the raise was for one reason only to ensure the books express a cash balance and a intent to move forward with P3 and confirmations of further proof , that is it .. that simple ..

Anyone now interested in buying IMM , IE the big fishes they have confirmation that a low ball offer will not be accepted and while they are in advanced neg , IMM needed a quick resolution for their accounts , hence Lanstead .. end of ..

The next RNS will be intent to buy .. however at this stage we can not expect more that £1 - £1.50 ..

The above is not financial advise ..

My thoughts are that the findings at this stage seem very promising and it is highly unlikely they will not come to fusion in Jok report , or the demand for those critical minerals will ever decrease now ..

So in ref to risk vs reward , any investor can clearly identify that the sp is so low , and none of the above seem priced in , that one would believe that positions will be taken here driving the Sp up to at least 1 p before official news of a take over ..